Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 7800

Next Previous
Drug Profile

RG 7800

Alternative Names: RG 7800; RO6885247; SMN2 gene-targeted therapy - PTC Therapeutics; SMN2-targeted therapeutic for spinal muscular atrophy - PTC Therapeutics/SMA Foundation/Roche

Latest Information Update: 31 Jul 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PTC Therapeutics
  • Developer Roche
  • Class Small molecules
  • Mechanism of Action Survival of motor neuron 1 protein stimulants; Survival of motor neuron 2 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Spinal muscular atrophy

Most Recent Events

  • 01 Jul 2016 Roche terminates the phase I/II MOONFISH trial in Spinal muscular atrophy (In children, In adolescents, In adults, In infants) in United Kingdom, Italy, Turkey, Switzerland, Canada, France, the Netherlands, Sweden and USA (NCT02240355)
  • 04 Oct 2015 Interim efficacy and adverse events data from a phase-I/II trial in Spinal muscular atrophy released by PTC Therapeutics
  • 19 Nov 2014 Phase-I/II clinical trials in Spinal muscular atrophy (In infants, In children, In adolescents, In adults) in Turkey, Italy and Switzerland (PO) (NCT02240355; EudraCT2014-002246-41)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top